Europe Prostate Cancer Diagnostics Market
Taille du marché en milliards USD
TCAC :
% 
 Période de prévision |
2021 –2028 |
 Taille du marché (année de référence) |
USD 636.30 Million |
 Taille du marché (année de prévision) |
USD 1,604.78 Million |
 TCAC |
% |
| Principaux acteurs du marché |
>Marché européen des médicaments de diagnostic du cancer de la prostate, par type de produit (instruments, réactifs et consommables et accessoires), type de diagnostic (tests de dépistage préliminaires, tests de confirmation), groupe d'âge (adulte, pédiatrique et gériatrie), type (adénocarcinome prostatique, carcinome à petites cellules et autres), stade (cancer de la prostate localisé, cancer de la prostate récurrent/avancé et cancer de la prostate résistant à la castration (métastatique et non métastatique), type d'échantillon (sang, tissu, urine et autres), utilisateurs finaux (laboratoires de diagnostic indépendants, hôpitaux, instituts de recherche sur le cancer, cliniques, centres de chirurgie ambulatoire et autres), canal de distribution (appel d'offres direct et vente au détail), pays (Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Pays-Bas, Suisse, Belgique et reste de l'Europe) Tendances et prévisions de l'industrie jusqu'en 2028
Analyse et perspectives du marché : marché européen du diagnostic du cancer de la prostate
Le marché du diagnostic du cancer de la prostate devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 12,5% au cours de la période de prévision de 2021 à 2028 et devrait atteindre 1 604,78 millions USD d'ici 2028 contre 636,30 millions USD en 2020. L'accent croissant mis sur la charge de morbidité et la sensibilisation croissante à la maladie sont les principaux moteurs qui propulsent le marché au cours de la période de prévision.
Des instruments, des réactifs, des consommables et des accessoires sont utilisés pour le diagnostic. Le test PSA, les examens rectaux numériques, l'IRM, le PET/CT scan, entre autres, sont des tests préliminaires et de confirmation utilisés dans le diagnostic du cancer de la prostate. La prévalence croissante du cancer de la prostate, l'augmentation de la recherche et du développement dans le domaine du diagnostic du cancer de la prostate, l'augmentation de la population gériatrique et le lancement de nouveaux produits pour le diagnostic du cancer de la prostate devraient stimuler la croissance du marché du diagnostic du cancer de la prostate. De plus, l'augmentation des investissements et du financement des acteurs émergents, la politique de remboursement des diagnostics du cancer de la prostate et les initiatives gouvernementales en faveur du diagnostic du cancer soutiennent la croissance du marché du diagnostic du cancer de la prostate.
La demande de diagnostics du cancer de la prostate a augmenté dans les pays développés comme dans les pays en développement, en raison de l'attention croissante portée à la mortalité due au cancer de la prostate. Le marché du diagnostic du cancer de la prostate est en croissance en raison de l'introduction de produits innovants, d'une sensibilisation accrue et de diverses initiatives gouvernementales. Le marché va croître au cours de la période prévue en raison de l'exploration des marchés émergents, des initiatives stratégiques des acteurs du marché et de la sensibilisation croissante aux problèmes capillaires.
Le rapport sur le marché du diagnostic du cancer de la prostate fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et local, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché, d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.
Portée et taille du marché européen du diagnostic du cancer de la prostate
Le marché du diagnostic du cancer de la prostate est classé en huit segments notables qui sont basés sur le type de produit, le type de diagnostic, la tranche d'âge, le type, le stade, le type d'échantillon, les utilisateurs finaux et le canal de distribution.
- Sur la base du type de produit, le marché du diagnostic du cancer de la prostate est segmenté en instruments, réactifs et consommables et accessoires. En 2021, le segment des réactifs et consommables domine le marché du diagnostic du cancer de la prostate car il comprend les produits de test PSA, qui sont le principal test recommandé pour les tests préliminaires. Le PSA mesure la protéine produite par les cellules de la prostate, qui constitue la première ligne de diagnostic du cancer de la prostate.
- Sur la base du type de diagnostic, le marché du diagnostic du cancer de la prostate est segmenté en tests de dépistage préliminaires et tests de confirmation. En 2021, le segment des tests de dépistage préliminaires domine le marché du diagnostic du cancer de la prostate, car le nombre de tests préliminaires dépasse de manière significative le nombre de tests de confirmation.
- Sur la base de la tranche d'âge, le marché du diagnostic du cancer de la prostate est segmenté en adulte, pédiatrique et gériatrique. En 2021, le segment gériatrique domine le marché du diagnostic du cancer de la prostate, car environ 60 % des cas sont diagnostiqués chez les hommes de plus de 65 ans. L'âge moyen du diagnostic du cancer de la prostate est de 66 ans. La maladie survient rarement chez les personnes de moins de 40 ans. Le nombre de nouveaux cas diagnostiqués chez les hommes noirs est 60 % plus élevé que le nombre de nouveaux cas diagnostiqués chez les hommes blancs.
- Sur la base du type, le marché du diagnostic du cancer de la prostate est segmenté en adénocarcinome prostatique, carcinome à petites cellules et autres. En 2021, le segment de l'adénocarcinome prostatique domine le marché du diagnostic du cancer de la prostate car plus de 95 % des cancers de la prostate sont des adénocarcinomes qui se développent dans les cellules glandulaires et la ligne de la prostate. Presque tous les hommes atteints d'un cancer de la prostate ont ce type. Il s'agit de la deuxième cause de décès par cancer chez les hommes. Une fois que le cancer atteint un certain stade, les cellules anormales se propagent à d'autres parties du corps, provoquant ainsi des métastases qui conduisent à dominer le segment du marché.
- On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III. Most of the men diagnosed and treated at the local or regional stages will be disease-free after five years. This type of cancer does not spread in any of the nearby tissues or to distant parts of the body. The stages present in localized prostate cancer are stage 1 and 2. The growth of tumor in low-risk localized prostate cancer is slow.
- On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.
- On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, Independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as this segment is specialized in conducting various prostate cancer diagnostics. Moreover, independent diagnostic laboratories enable the facilitation of robust, on-time, cost-effective and high quality diagnostic care and services in safe healthcare environment and are convenient for consulting physician/healthcare institution to outsource bulk diagnostics tests to independent diagnostic laboratories for better customer services.
- On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers.
Prostate Cancer Diagnostics Market Country Level Analysis
The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.
The countries covered in the prostate cancer diagnostics market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe.
Europe is expected to grow with the highest CAGR in the forecasted period as in the growing prevalence of prostate cancer and favorable reimbursement landscape. Germany is expected to dominate in the Europe market primarily due to increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market
Prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis
Prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.
The major companies providing prostate cancer diagnostics are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, OPKO Health Inc., Abott, Beckman Coulter, Inc. (A Subsidiary of Danaher), among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.
For instance,
- En décembre 2020, Fujirebio Europe a annoncé avoir reçu une somme de 876 000 USD de Flanders Innovation & Entrepreneurship (VLAIO) pour développer une plateforme de diagnostic clinique in vitro (DIV) intégrant des technologies de séquençage de troisième génération (TGS). Il s'agit de développer des DIV rentables, précis et portables. Cela améliorera le profil de l'entreprise et augmentera la recherche et le développement de l'entreprise.
La collaboration, les coentreprises et d’autres stratégies des acteurs du marché améliorent le marché de l’entreprise sur le marché du diagnostic du cancer de la prostate, ce qui offre également l’avantage à l’organisation d’améliorer son offre pour le marché du diagnostic du cancer de la prostate.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- product type LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- MARKET end users coverage GRID
- vendor share analysis
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- Epidemiology
- COMPARATIVE ANALYSIS WITH PARENT MARKET
- REGULATORY FRAMEWORK: EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
- REGULATORY SCENARIO IN EUROPEAN UNION
- market overview
- drivers
- INCREASING PREVALENCE OF PROSTATE CANCER
- INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
- INCREASE IN GERIATRIC POPULATION
- LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
- DISEASE CAUSING PROSTATE CANCER
- RESTRAINTS
- CONTROVERSY RELATED TO PSA TESTING
- HIGH COST OF DIAGNOSTICS PROCEDURE
- LACK OF SKILLED AND CERTIFIED PROFESSIONALS
- OPPORTUNITIES
- RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
- REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
- GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
- RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
- Challenges
- STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
- OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
- INACCURATE DIAGNOSIS RESULTS
- IMPACT OF COVID-19 ON EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY CHAIN
- STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
- KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
- CONCLUSION
- Europe prostate cancer diagnostics market, BY product type
- overview
- reagents & consumables
- instruments
- accessories
- Europe prostate cancer diagnostics market, BY DIAGNOSTICS TYPE
- overview
- preliminary screening tests
- Prostate-Specific Antigen (PSA) Test
- Digital Rectal Exam (DRE) Test
- Confirmatory Tests
- PCA3 Test
- biopsy
- imaging tests
- ULTRASOUND
- MAGNETIC RESONANCE IMAGING (MRI)
- MULTIPARAMETRIC MRI
- MRI FUSION-GUIDED PROSTATE BIOPSY
- CT SCAN
- BONE SCAN
- PET/CT SCAN
- biomarker
- RNA BIOMARKERS
- DNA BIOMARKERS
- PROTEIN BIOMARKERS
- Europe prostate cancer diagnostics market, By type
- overview
- PROSTATIC ADENOCARCINOMA
- small cell carcinoma
- Others
- Europe prostate cancer diagnostics market, BY AGE GROUP
- overview
- geriatrics
- adult
- Pediatric
- Europe prostate cancer diagnostics market, BY Stage
- overview
- LOCALIZED PROSTATE CANCER
- RECURRENT/ADVANCED PROSTATE CANCER
- CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
- Europe prostate cancer diagnostics market, BY sample type
- overview
- Blood
- tissue
- urine
- others
- Europe prostate cancer diagnostics market, BY end users
- overview
- Independent Diagnostic Laboratories
- hospitals
- Clinics
- Ambulatory Surgical Centers
- Cancer Research Institutes
- others
- Europe prostate cancer diagnostics market, BY Distribution Channel
- overview
- direct tender
- retail sales
- Europe prostate cancer diagnostics market, BY Country
- GERMANY
- FRANCE
- u.k.
- iTALY
- SPAIN
- RUSSIA
- SWITZERLAND
- NETHERLANDS
- TURKEY
- bELGIUM
- REST OF EUROPE
- EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY landscape
- company share analysis: europe
- SWOT
- company profile
- F. Hoffmann-La Roche Ltd
- COMPANY SNAPSHot
- REVENUE ANALYSIS
- product Portfoli0
- RECENT DEVELOPMENTs
- Abbott
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- siemens HEALTHCARE gmbh
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- OPko HEALTH INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Beckman Coulter, Inc. (A Subsidiary of Danaher)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- acon laboratories inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Biomerieux sa
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Diasorin s.p.a
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLI0
- RECENT DEVELOPMENTS
- Eurolyser Diagnostica GmbH
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- FUJIREBIO
- COMPANY SNAPSHOT
- PRODUCT PORTFOLI
- RECENT DEVELOPMENTS
- GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- HOLOGIC, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- MDXHEALTHCARE
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Myraid genetics, inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Prostatype Genomics
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- PROTEOMEDIX
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
Liste des tableaux
TABLE 1 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER
TABLE 2 Europe prostate cancer diagnostics market, By product type, 2019-2028 (USD Million)
TABLE 3 Europe prostate cancer diagnostics market, By product type, 2019-2028 (UNits)
TABLE 4 Europe prostate cancer diagnostics market, By DIAGNOSTICS TYPE, 2019-2028 (USD Million)
TABLE 5 EUROPE preliminary screening tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)
TABLE 6 EUROPE Confirmatory tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)
TABLE 7 EUROPE imaging tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)
TABLE 8 EUROPE Magnetic Resonance Imaging (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)
TABLE 9 EUROPE biomarker IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)
TABLE 10 Europe prostate cancer diagnostics market, By type, 2019-2028 (USD million)
TABLE 11 Europe prostate cancer diagnostics market, By age group, 2019-2028 (USD Million)
TABLE 12 Europe prostate cancer diagnostics market, By Stage, 2019-2028 (USD Million)
TABLE 13 Europe prostate cancer diagnostics market, By Sample Type, 2019-2028 (USD Million)
TABLE 14 Europe prostate cancer diagnostics market, By End Users, 2019-2028 (USD Million)
TABLE 15 Europe prostate cancer diagnostics market, By distribution channel, 2019-2028 (USD Million)
TABLE 16 Europe prostate cancer diagnostics market, By country, 2019-2028 (USD Million)
TABLE 17 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 18 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 19 GERMANY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 20 GERMANY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 21 GERMANY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 22 GERMANY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 23 GERMANY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 24 GERMANY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 25 GERMANY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 26 GERMANY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 27 GERMANY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 28 GERMANY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 29 GERMANY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 30 GERMANY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 31 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 32 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 33 FRANCE Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 34 FRANCE Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 35 FRANCE Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 36 FRANCE Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 37 FRANCE Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 38 FRANCE Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 39 FRANCE Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 40 FRANCE Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 41 FRANCE Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 42 FRANCE Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 43 FRANCE Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 44 FRANCE Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 45 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 46 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 47 U.K. Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 48 U.K. Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 49 U.K. Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 50 U.K. Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 51 U.K. Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 52 U.K. Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 53 U.K. Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 54 U.K. Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 55 U.K. Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 56 U.K. Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 57 U.K. Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 58 U.K. Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 59 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 60 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 61 ITALY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 62 ITALY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 63 ITALY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 64 ITALY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 65 ITALY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 66 ITALY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 67 ITALY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 68 ITALY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 69 ITALY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 70 ITALY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 71 ITALY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 72 ITALY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 73 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 74 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 75 SPAIN Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 76 SPAIN Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 77 SPAIN Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 78 SPAIN Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 79 SPAIN Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 80 SPAIN Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 81 SPAIN Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 82 SPAIN Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 83 SPAIN Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 84 SPAIN Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 85 SPAIN Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 86 SPAIN Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 87 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 88 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 89 RUSSIA Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 90 RUSSIA Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 91 RUSSIA Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 92 RUSSIA Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 93 RUSSIA Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 94 RUSSIA Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 95 RUSSIA Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 96 RUSSIA Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 97 RUSSIA Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 98 RUSSIA Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 99 RUSSIA Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 100 RUSSIA Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 101 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 102 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 103 SWITZERLAND Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 104 SWITZERLAND Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 105 SWITZERLAND Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 106 SWITZERLAND Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 107 SWITZERLAND Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 108 SWITZERLAND Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 109 SWITZERLAND Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 110 SWITZERLAND Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 111 SWITZERLAND Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 112 SWITZERLAND Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 113 SWITZERLAND Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 114 SWITZERLAND Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 115 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 116 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 117 NETHERLANDS Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 118 NETHERLANDS Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 119 NETHERLANDS Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 120 NETHERLANDS Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 121 NETHERLANDS Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 122 NETHERLANDS Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 123 NETHERLANDS Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 124 NETHERLANDS Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 125 NETHERLANDS Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 126 NETHERLANDS Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 127 NETHERLANDS Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 128 NETHERLANDS Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 129 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 130 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 131 TURKEY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 132 TURKEY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 133 TURKEY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 134 TURKEY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 135 TURKEY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 136 TURKEY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 137 TURKEY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 138 TURKEY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 139 TURKEY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 140 TURKEY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 141 TURKEY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 142 TURKEY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 143 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)
TABLE 144 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)
TABLE 145 BELGIUM Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 146 BELGIUM Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 147 BELGIUM Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 148 BELGIUM Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 149 BELGIUM Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 150 BELGIUM Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)
TABLE 151 BELGIUM Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)
TABLE 152 BELGIUM Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)
TABLE 153 BELGIUM Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)
TABLE 154 BELGIUM Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)
TABLE 155 BELGIUM Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)
TABLE 156 BELGIUM Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)
TABLE 157 rest of Europe prostate cancer diagnostics market, By Product Type, 2019-2028 (USD Million)
Liste des figures
FIGURE 1 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: segmentation
FIGURE 2 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: data triangulation
FIGURE 3 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: regional VS country MARKET ANALYSIS
FIGURE 5 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MARKET end users coverage GRID
FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER and INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICs are DRIVing THE EUROPE PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 to 2028
FIGURE 13 REAGENTS & CONSUMABLES segment is expected to account for the largest share of the EUROPE PROSTATE CANCER DIAGNOSTICS MARKETin 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
FIGURE 15 GERIATRIC POPULATION IN THE EUROPEAN REGION
FIGURE 16 Europe prostate cancer diagnostics market : BY product type, 2020
FIGURE 17 Europe prostate cancer diagnostics market : BY product type, 2021-2028 (USD Million)
FIGURE 18 Europe prostate cancer diagnostics market : BY product type, CAGR (2021-2028)
FIGURE 19 PROSTATE CANCER DIAGNOSTICS market : BY product type, LIFELINE CURVE
FIGURE 20 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, 2020
FIGURE 21 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE 2021-2028 (USD Million)
FIGURE 22 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, CAGR (2021-2028)
FIGURE 23 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, LIFELINE CURVE
FIGURE 24 Europe prostate cancer diagnostics market : By type, 2020
FIGURE 25 Europe prostate cancer diagnostics market : By type, 2021-2028 (USD Million)
FIGURE 26 Europe prostate cancer diagnostics market : By type, CAGR (2021-2028)
FIGURE 27 Europe prostate cancer diagnostics market : By type, LIFELINE CURVE
FIGURE 28 Europe prostate cancer diagnostics market : BY age group, 2020
FIGURE 29 Europe prostate cancer diagnostics market : BY age group, 2021-2028 (USD Million)
FIGURE 30 Europe prostate cancer diagnostics market : BY age group, CAGR (2021-2028)
FIGURE 31 Europe prostate cancer diagnostics market : BY age group, LIFELINE CURVE
FIGURE 32 Europe prostate cancer diagnostics market : BY stage, 2020
FIGURE 33 Europe prostate cancer diagnostics market : BY stage, 2021-2028 (USD Million)
FIGURE 34 Europe prostate cancer diagnostics market : BY stage, CAGR (2021-2028)
FIGURE 35 Europe prostate cancer diagnostics market : BY stage, LIFELINE CURVE
FIGURE 36 Europe prostate cancer diagnostics market : BY sample type, 2020
FIGURE 37 Europe prostate cancer diagnostics market : BY sample type, 2021-2028 (USD Million)
FIGURE 38 Europe prostate cancer diagnostics market : BY sample type, CAGR (2021-2028)
FIGURE 39 Europe prostate cancer diagnostics market : BY sample type, LIFELINE CURVE
FIGURE 40 Europe prostate cancer diagnostics market : BY end users, 2020
FIGURE 41 Europe prostate cancer diagnostics market : BY end users, 2021-2028 (USD Million)
FIGURE 42 Europe prostate cancer diagnostics market : BY end users, CAGR (2021-2028)
FIGURE 43 Europe prostate cancer diagnostics market : BY end users, LIFELINE CURVE
FIGURE 44 Europe prostate cancer diagnostics market : BY distribution channel, 2020
FIGURE 45 Europe prostate cancer diagnostics market : BY distribution channel, 2021-2028 (USD Million)
FIGURE 46 Europe prostate cancer diagnostics market : BY distribution channel, CAGR (2021-2028)
FIGURE 47 Europe prostate cancer diagnostics market : BY distribution, LIFELINE CURVE
FIGURE 48 Europe prostate cancer diagnostics market : SNAPSHOT (2020)
FIGURE 49 Europe prostate cancer diagnostics market : BY COUNTRY (2020)
FIGURE 50 Europe prostate cancer diagnostics market : BY COUNTRY (2021 & 2028)
FIGURE 51 Europe prostate cancer diagnostics market : BY COUNTRY (2020 & 2028)
FIGURE 52 Europe prostate cancer diagnostics market : BY Product type (2021-2028)
FIGURE 53 europe Prostate cancer diagnostics market: company share 2020 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
